Eutylone
Viewing r1 — May 7, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Eutylone (N-ethylbutylone) is a synthetic stimulant of the cathinone class. It is a structural relative of methylone, with stronger dopamine selectivity and weaker serotonergic character. It blocks dopamine and norepinephrine reuptake while partially releasing serotonin, amplifying reward signaling with mild mood-brightening.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
methylone, mephedrone, MDPV +2 moremethylone, mephedrone, MDPV, cocaine, amphetamine show less
Synthesized in 1967 by Boehringer as part of a patent series, it attracted no pharmacological attention for five decades.[2] When authorities scheduled N-ethylpentylone in 2019, illicit markets rapidly adopted eutylone as an uncontrolled replacement.[3] By 2022–2023 it ranked among the three most prevalent new psychoactive substances detected globally.[4]
Subjective effects include stimulation, euphoria, increased energy, mild empathogenic warmth, and social disinhibition.[5] The experience is more stimulant-forward than MDMA — an energized, buzzing state with modest prosocial warmth rather than full emotional immersion. Paranoia, agitation, compulsive redosing, and rapid heart rate are characteristic unwanted effects.
Animal studies confirm rewarding properties, and one death has been attributed to eutylone alone — no lethal threshold is established.[6] The dominant hazard is misrepresentation: eutylone is frequently sold as MDMA, exposing users to unknown doses, and overheating is the primary life-threatening mechanism.[3] The evidence base is extremely thin — almost all data come from forensic casework and animal models, with no controlled human studies.
History[edit]
Discovery
Eutylone was first synthesized in 1967 by Boehringer as part of a patent covering aryl-aminoketone derivatives.[2] It was never selected for pharmaceutical development and attracted no pharmacological attention for the following five decades.
Market emergence and global spread
Eutylone first appeared in European drug monitoring in 2014,[7][5] but prevalence stayed low until 2019. When the DEA scheduled N-ethylpentylone in August 2019, forensic labs documented rapid market substitution toward eutylone.[3][8] By 2022–2023 it ranked among the top three most prevalent new psychoactive substances globally.[4][9]
Scheduling
The WHO Expert Committee on Drug Dependence reviewed eutylone in October 2021 and recommended placement in Schedule II of the Convention on Psychotropic Substances.[5] International scheduling was formalized in 2022,[10] and most jurisdictions now control it by name or under generic cathinone provisions.
The compound circulates under the chemical synonyms bk-EBDB, N-ethylbutylone, and β-keto-EBDB.[3] In pharmacology literature it is classified as a third-generation synthetic cathinone — terminology distinguishing it from earlier bath-salt waves.[11][12] Eutylone's reputation is shaped largely by what it pretends to be: it is frequently pressed into tablets sold as MDMA or mixed into blends marketed as tusi (pink cocaine).[13]
Chemistry[edit]
Structural class
Eutylone belongs to the methylenedioxy cathinone family — the same structural series as methylone and butylone. The methylenedioxy ring gives these compounds partial serotonergic character that plain cathinones lack.[14] Compared to methylone, eutylone has an N-ethyl group and an ethyl chain at the α-carbon, making it more lipophilic and shifting its profile toward stronger dopamine selectivity.[14][7]
Molecular identity
| Molecular formula | C₁₃H₁₇NO₃ |
| Molecular weight | 235.28 g/mol |
The molecule features a methylenedioxy ring fused to the phenyl group, a β-keto group at the benzylic position, and an ethyl chain at the α-carbon.[15]
Pharmacology[edit]
Mechanism of action
Eutylone blocks dopamine and norepinephrine reuptake — keeping both active in the synapse longer — while also partially releasing serotonin.[1] Dopamine blockade is its dominant action, about ten times more potent than its effect on norepinephrine.[1] This positions eutylone between cocaine (dopamine reuptake inhibitor) and MDMA (full monoamine releaser) — a distinction confirmed in animal behavioral studies.[16][17]
Pharmacokinetics
No controlled human pharmacokinetic studies have been published for eutylone. No data exist for oral bioavailability, peak blood levels, half-life, or protein binding in humans. All available data derive from forensic casework and laboratory metabolite studies.Eutylone is broken down primarily by reduction of the β-keto group, with additional liver processing.[3][18] The keto-reduced metabolite is the most reliable urine detection target.[18] Methylenedioxy cathinones like eutylone are more stable in biological samples than related compounds, so blood concentrations measured at autopsy may underestimate actual levels at the time of ingestion.[19]
Neuroscience[edit]
Where it acts
Eutylone's primary target is the mesolimbic pathway — the brain's reward circuit running from the ventral tegmental area to the nucleus accumbens.[1] Blocking dopamine reuptake there amplifies reward signaling in the same way cocaine does. Norepinephrine blockade adds arousal and cardiovascular activation through the brain's alerting systems.
The partial serotonin release distinguishes eutylone from pure dopamine blockers and is expected to produce mild mood-brightening and prosocial effects.[1] Whether it engages deeper empathogenic mechanisms seen with MDMA — such as oxytocin release or reduced fear responses — remains untested.
Why it matters
Repeated eutylone exposure selectively reduces the compound's own aversive effects while leaving responses to cocaine and MDMA unaffected.[16] Eutylone history enhances cocaine reward without enhancing MDMA reward.[17] This suggests eutylone specifically reshapes dopaminergic reinforcement — consistent with the pattern that dopamine-dominant compounds drive strong craving while their pleasure ceiling remains constrained.
Whether eutylone causes lasting changes in brain structure is unknown — no systematic studies exist for cathinones on neural growth pathways.[20] The ceiling on eutylone's serotonin release may reduce serotonin-related toxicity risk compared to MDMA, but no data exist to confirm this.[20] Whether individual stereoisomers differ in dopamine-versus-serotonin selectivity has not been tested.
Subjective Effects[edit]
Eutylone's experience is primarily stimulant — heightened energy, mood elevation, and social disinhibition dominate the state. A mild serotonergic warmth adds modest prosocial coloring and tactile sensitivity, but these remain far less pronounced than with methylone or MDMA.[5]
Among synthetic cathinones, eutylone sits between the empathogenic warmth of methylone and the purely dopaminergic push of compounds like dibutylone. Compared to MDMA it is more stimulant-forward and less emotionally immersive; compared to cocaine it offers a warmer affective tone with potentially longer stimulation.[16][17]
Effect Grid
Clear stimulation with pronounced cognitive euphoria, energy, and sociability enhancement. Disinhibition and communication enhancement are prominent. The partial entactogenic warmth from SERT activity is most apparent at this range — a mild empathy enhancement and tactile euphoria that falls well short of MDMA's emotional immersion but distinguishes eutylone from purely dopaminergic stimulants.
Cardiovascular activation becomes evident: tachycardia, mild body high, and appetite suppression are typical. Bruxism, dry mouth, excessive sweating, and pupil dilation are common. Temperature dysregulation begins. Wakefulness is pronounced, and insomnia is likely for 4–6 hours post-dose.
Compulsive redosing urge may emerge at this tier — eutylone's DAT-dominant profile generates strong craving. Users expecting MDMA-like duration may redose inappropriately due to the shorter, more stimulant-forward character.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Touch enhancement
Dry mouth · Insomnia · Pupil dilation · Restlessness · Body high · Excessive sweating · Heart rate perception changes · Physical fatigue · Respiratory stimulation · Bodily lightness · Breathing alteration · Dehydration sensation · Muscle tension · Nausea · Bruxism · Dizziness · Headache · Sexual arousal enhancement · Spontaneous body sensations · Tactile euphoria · Tingling / electric sensations · Trembling · Vomiting
Body high · Excessive sweating · Heart rate perception changes · Physical fatigue · Respiratory stimulation · Bodily lightness · Breathing alteration · Dehydration sensation · Muscle tension · Nausea · Bruxism · Dizziness · Headache · Sexual arousal enhancement · Spontaneous body sensations · Tactile euphoria · Tingling / electric sensations · Trembling · Vomiting
Motivation enhancement · Aesthetic enhancement · Analysis enhancement · Cognitive impairment · Focus enhancement · Immersion enhancement · Information processing enhancement · Introspection enhancement · Novelty enhancement · Openness enhancement · Pattern recognition enhancement · Suggestibility enhancement · Thought connectivity · Thought loops · Creativity enhancement · Humor enhancement · Language enhancement · Thought organization · Delusions of sobriety · Confusion · Thought disorganization
Cognitive impairment · Focus enhancement · Immersion enhancement · Information processing enhancement · Introspection enhancement · Novelty enhancement · Openness enhancement · Pattern recognition enhancement · Thought connectivity · Thought loops · Creativity enhancement · Humor enhancement · Language enhancement · Thought organization · Delusions of sobriety · Confusion · Thought disorganization
Empathy enhancement · Irritability · Dysphoria · Emotional lability · Anxiety suppression · Simultaneous emotions
Anxiety suppression · Simultaneous emotions
Communication enhancement · Disinhibition · Emotional susceptibility · Trust enhancement · Flow state · Ego inflation · Derealization
Flow state · Ego inflation · Derealization
Timeline
Initial awareness of mild stimulation and subtle energy increase. Mood may brighten slightly. Effects are easily dismissed as placebo at the lower end of this window.
Rapid escalation of stimulant effects with emerging euphoria and sociability. Heart rate increases noticeably. Mild empathogenic warmth from partial SERT activity may become apparent.
Maximum stimulation, cognitive euphoria, and sociability enhancement. DAT-dominant effects are most pronounced — energy, focus, and disinhibition peak. Appetite suppression and wakefulness are strong.
Gradual decline in stimulation with residual sympathomimetic activation. Euphoria fades while cardiovascular effects (tachycardia, vasoconstriction) may persist. Irritability and restlessness may emerge during this phase.
Post-stimulant residual effects — wakefulness, restlessness, appetite suppression fading, and possible low mood or anhedonia. Physical fatigue may contrast with continued insomnia.
⚠ Avoid driving for at least 6 hours after last dose due to residual sympathomimetic effects, potential fatigue rebound, and cognitive impairment.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 14 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- methylone · mephedrone · MDPV
Toxicity
Acute toxicity
No lethal dose has been established for eutylone.safety citation needed One published fatality attributes death solely to eutylone: a 32-year-old man died of cardiac arrest after a single use, with a cardiac blood concentration of 4,290 ng/g.[6] Autopsy found no signs of muscle breakdown, pointing to acute heart rhythm disturbance as the mechanism.[6]
Blood concentrations in forensic cases span an extreme range — from 1.2 to 11,000 ng/mL across 83 cases in 13 US states.[3] Two non-fatal cases showed survival at 1,374 and 1,536 ng/mL, overlapping the lower end of fatal case data.[10]
Adulteration hazard
Eutylone is frequently sold as MDMA in illicit markets.[3] It has been identified in tusi (pink cocaine) blends in Miami-Dade fatality cases, combined with ketamine, MDMA, and other substances.[13] Standard colorimetric reagent tests cannot distinguish eutylone from MDMA; laboratory confirmation is required.[3]
- Heart and circulation: Rapid heart rate, high blood pressure, heart rhythm disturbances
- Temperature: Dangerous overheating — the primary life-threatening mechanism, especially in hot environments with physical exertion
- Brain and behavior: agitation, confusion, delirium, paranoia, psychosis, hallucinations, seizures
- Serotonin-related: Features of serotonin syndrome possible given partial serotonin-releasing activity
- Muscles and kidneys: Muscle breakdown with potential kidney damage
- Gut: nausea, vomiting
Neurotoxicity
No eutylone-specific neurotoxicity studies exist. Synthetic cathinones as a class can produce brain damage including encephalopathy, seizures, and excited delirium.[20] Methylenedioxy cathinones appear to cause moderate neurotoxicity in animal models — less severe than amphetamines per dose — but eutylone-specific thresholds are unknown.[20]
Psychological risks
Eutylone's aversive effects fade with repeated use while rewarding effects persist or strengthen.[16] This selective fading of negative feedback is a risk factor for dose escalation and compulsive use.
Case reports describe paranoia, delirium, hallucinations, and agitation as acute psychiatric effects.[5] Users expecting MDMA's empathogenic warmth and encountering a stimulant-dominant experience instead may develop confusion, anxiety, or panic.
Tolerance and dependence
Animal models show rewarding effects across a wide dose range (3–32 mg/kg), with rewarding and unpleasant effects separable and dose-dependent.[11][12] The WHO concluded eutylone's profile suggests likelihood of abuse.[5]
Repeated exposure selectively reduces aversive effects without affecting responses to cocaine or MDMA.[16] No human tolerance data, cross-tolerance profiles, or characterized withdrawal exist. Class-level reports describe post-use fatigue, depressed mood, and craving after cessation of synthetic cathinone use.
Drug interactions
No published interaction studies exist for eutylone.safety citation needed
Monoamine oxidase inhibitors (MAOIs — phenelzine, tranylcypromine, selegiline, moclobemide): highest-risk combination. Blocking monoamine breakdown while eutylone simultaneously amplifies monoamine signaling creates risk of dangerous serotonin overload and severe blood pressure spikes.
Serotonergic medications (SSRIs, SNRIs, triptans, tramadol): add to serotonergic load through eutylone's partial serotonin-releasing activity. The ceiling on eutylone's serotonin release may offer some protection compared to full releasers, but this is theoretical.
Stimulants (cocaine, amphetamines, methamphetamine): additive cardiovascular strain — high blood pressure, rapid heart rate, and overheating. Eutylone history enhances cocaine reward in animal models,[17] suggesting effects beyond simple addition.
Depressants (benzodiazepines, opioids, alcohol, GHB): may mask stimulant overdose warning signs. The polydrug pattern documented in forensic fatality series — stimulant toxicity obscured by concurrent depressant use — represents a significant hazard.[3][23]
Contraindications
No eutylone-specific contraindication studies exist.safety citation needed
Heart conditions (absolute): Pre-existing heart rhythm disorders, high blood pressure, and coronary artery disease. Eutylone directly increases cardiac workload and rhythm disturbance risk. The published fatality involved cardiac arrest.[6]
MAOI therapy (absolute): Risk of dangerous serotonin overload and severely elevated blood pressure through dual blockade of monoamine breakdown and reuptake.
Seizure disorders (absolute): Synthetic cathinones lower the seizure threshold; seizures appear in eutylone's clinical presentation.[5]
Psychotic spectrum disorders (relative): Paranoia, delirium, and psychosis are documented with eutylone use.[5] Pre-existing vulnerability elevates risk.
Liver impairment (relative): Eutylone is eliminated primarily through the liver; impaired function may prolong exposure and increase toxic metabolite buildup.[24]
Kidney impairment (relative): Muscle breakdown is a documented complication of stimulant cathinone toxicity, increasing risk of acute kidney damage in those with pre-existing compromise.[5]
Hot environments with physical exertion (relative): Heat and activity amplify eutylone's disruption of temperature regulation — the primary life-threatening mechanism in cathinone toxicity.
Pregnancy (absolute): No reproductive toxicity data exist. Stimulant-driven cardiovascular stress poses theoretical risks to fetal development and placental blood flow.safety citation needed
Harm Reduction[edit]
Forms & Identification
Eutylone is one of the most commonly misrepresented substances in current illicit markets. The Marquis reagent test produces a similar reaction for both eutylone and MDMA — a positive result does not confirm MDMA. Only laboratory-grade analysis (GC-MS or LC-MS/MS) can confirm eutylone's presence or absence.
In pressed tablet form, eutylone is visually indistinguishable from MDMA. In polydrug blends like tusi, it appears alongside multiple other substances at unknown ratios, compounding the identification challenge.
Guidelines
- Test all substances before use — Marquis alone is insufficient. Multi-reagent testing narrows possibilities, but only laboratory analysis confirms identity.
- Start with the lowest possible dose and wait at least 90 minutes before considering redosing. Eutylone's pharmacokinetics are uncharacterized; onset and peak timing are unpredictable.
- Stay cool. Avoid sustained dancing or heavy exertion in hot environments. Take regular breaks in ventilated areas.
- Hydrate steadily but do not overhydrate — approximately 250 mL (one cup) of water per hour of activity.
- Avoid redosing. Eutylone's reward profile promotes compulsive redosing; the aversive effects that normally signal "enough" fade with repeated use while cardiovascular strain accumulates.
- Have a sober, informed companion present who knows what was taken and can monitor for overheating or behavioral changes.
Set & Setting
Hot, crowded environments with sustained physical activity — dance floors, festivals, packed venues — amplify the overheating risk that represents eutylone's primary life-threatening mechanism. Cool, ventilated spaces with access to water significantly reduce this danger.
Eutylone is frequently consumed unknowingly, so preparation is often impossible. Those who have confirmed eutylone's presence should choose environments with temperature control, limit physical exertion, and ensure a trusted companion is present.
Aftercare & integration. The stimulant comedown following eutylone use typically involves fatigue, low mood, and difficulty sleeping. Prioritize sleep — even if it requires a dark, quiet room and patience. Eat nutritious food as appetite returns; stimulant use depletes energy reserves.
Avoid redosing to manage the comedown. The urge to take more to offset fatigue is a predictable consequence of dopamine depletion. Physical recovery generally takes 24–48 hours; persistent low mood beyond several days warrants professional attention.
Recovery & Support
Eutylone's dopamine-dominant profile and compulsive-redosing potential can lead to patterns of escalating use. If use has become difficult to control, reducing frequency before stopping entirely may ease the transition. Stimulant-specific support resources include SAMHSA's National Helpline (1-800-662-4357), local harm reduction organizations, and peer support communities.
No eutylone-specific withdrawal has been characterized, but class-level reports describe fatigue, depressed mood, and craving after cessation of synthetic cathinone use. Professional support can help manage these symptoms.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
Most eutylone experiences involve manageable stimulation. Seek immediate help if any of the following occur: chest pain or irregular heartbeat, seizure or convulsions, body temperature hot to the touch through clothing, loss of consciousness, severe confusion or inability to communicate, or uncontrollable agitation with violent behavior.
Immediate steps
- Call emergency services immediately if the person is unconscious, seizing, or dangerously overheated.
- Move the person to a cool, quiet area and remove excess clothing.
- Apply cool water to skin — especially neck, armpits, and groin — to lower body temperature.
- Do not restrain the person unless there is immediate danger to themselves or others.
- Do not induce vomiting.
- If the person is unconscious but breathing, place them in the recovery position.
What to tell the dispatcher
State what was taken (or suspected), how much, when, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who seek help for drug-related emergencies — providing honest information can save a life.
Legal Status[edit]
Eutylone is now controlled in most jurisdictions, recommended for international scheduling by the WHO in 2021[5] and formally placed in Schedule II of the Convention on Psychotropic Substances in 2022.[10]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Controlled since March 7, 2014 as a positional isomer of pentylone. Specific listing with dedicated DEA code number established April 10, 2023 (88 FR 21101).[25] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Controlled under generic cathinone provisions.citation needed |
| European Union | Monitored since 2014; scheduled 2022 | EMCDDA Early Warning System monitoring since 2014.[7] WHO-recommended Schedule II placement implemented 2022. Individual member state implementation varies. |
| Australia | Controlled substance | Listed by the Australian Office of Drug Control.citation needed |
| New Zealand | Controlled (Misuse of Drugs Act 1975) | Covered by cathinone provisions. Among the highest mass-load NPS detected in NZ wastewater surveillance.[9] |
| International (UN) | Schedule II (Convention on Psychotropic Substances 1971) | WHO ECDD 44th meeting (October 2021) recommendation;[5] scheduling effective 2022.[10] |
references
- [1]
- [2]
- [3]
- [4] ^abNadarajan D et al. (2026) Wastewater analysis as a global toxicovigilance tool for the monitoring of new psychoactive substances — Water Research doi:10.1016/j.watres.2025.124847
- [5]
- [6] ^abcdNakamura M, Takaso M, Takeda A, Hitosugi M (2022) A fatal case of intoxication from a single use of eutylone: Clinical symptoms and quantitative analysis results — Legal Medicine (Tokyo) doi:10.1016/j.legalmed.2022.102085